QURE Share Price Performance
US$59.97
54.36 (968.98%)
9.8% undervalued intrinsic discount
US$66.50
Fair Value
Price US$59.97
AnalystConsensusTarget US$66.50
Fair ValueUS$66.50
Share PriceUS$59.97
9.8% undervalued intrinsic discount
uniQure N.V. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 21 Fair Values set on narratives written by author
QURE Community Narratives
AN
Fair Value US$66.5 9.8% undervalued intrinsic discount
AMT-130 Approval Will Transform Huntington's Treatment Pipeline
1users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
Recent QURE News & Updates
uniQure N.V. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -3.23
- Gross Margin
- -850.06%
- Net Profit Margin
- -1,387.98%
- Debt/Equity Ratio
- -12,668.0%
uniQure N.V. Competitors
Snowflake Analysis
About QURE
- Founded
- 1998
- Employees
- 209
- CEO
- WebsiteView website
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Dutch Market Performance
- 7 Days: 1.2%
- 3 Months: 8.0%
- 1 Year: 9.4%
- Year to Date: 15.4%
The market is up 1.2% over the last week, with the Information Technology sector leading the way, up 1.9%. On the other hand, with a decline of 4.0%, the Communication Services sector is lagging behind. In the last year, the market has climbed 9.4%. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›